Holzer & holzer, llc reminds shareholders of july 5, 2024 lead plaintiff deadline in altimmune, inc. (alt) class action – investors with significant losses encouraged to contact the firm

Atlanta, june 26, 2024 (globe newswire) -- a shareholder class action lawsuit has been filed against altimmune, inc. (“altimmune” or the “company”) (nasdaq: alt). the lawsuit alleges that defendants made materially false and misleading statements and/or failed to disclose material adverse information regarding the company's business, operations, and prospects, including allegations that: (i) altimmune overstated the potential for pemvidutide to stand out from competing glp-1 agonists based on the drug's efficacy and tolerability results observed in the momentum trial; (ii) accordingly, the momentum trial results were less significant to pemvidutide's clinical, commercial, and competitive prospects than defendants had led investors to believe; and (iii) as a result of all the foregoing, defendants had overstated altimmune's prospects for finding a strategic partner to develop pemvidutide.
ALT Ratings Summary
ALT Quant Ranking